据The Information：人工智能云初创公司Fireworks获40亿美元新融资，该公司的Fireworks AI旨在帮助企 业更快地运行开源模型。 ...

Nov Inc. (NOV) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non- recurring items. What's Next for Nov Inc.? While Nov Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is t ...

1.【 字节跳动开源AI Agent开发平台"扣子" 】7月28日消息，字节跳动旗下AI Agent开发平台"扣 子"（Coze）宣布正式开源，涵盖Coze Studio开发平台与Coze Loop运维平台两大核心项目，全面支持智能 体的开发、测试及调优。项目采用Apache 2.0许可证，允许商用且提供专利授权，旨在推动全球开发者协 作创新。（DoNews） 扫码订阅 AIGC 产业日报， 精选行业新闻，帮你省时间！ 此外，如果您还想 查公司、找项目、看行业，深入了解人形机器人、商业航天、AGI等热门赛道 ，欢迎加入睿兽分析会员，解锁相关行业图谱和报告等。 2. 【全球首款多模态梦境脑机接口设备发布】7月28日消息，据广东省智能科学与技术研究院公众号消 息，7月27日"2025睡眠神经调控医学研讨会暨梦境脑机接口创新产品发布会"在横琴粤澳深度合作区举 行，广东省智能科学与技术研究院与燧人医疗发布了联合研发的首款多模态梦境脑机接口设备"梦邻"， 据介绍该设备攻克了信号采集稳定性、算法优化、小型化及易用性等技术难题，通过"枕头"形态设计， 将脑机接口技术与日常睡眠场景结合，为"精准睡眠干预"与"主动健康管理"提 ...

Celestica (CLS 1.87%), a global electronics manufacturing services provider with a focus on Advanced Technology Solutions and Connectivity & Cloud Solutions, reported earnings for Q2 2025 on July 28, 2025. The company delivered GAAP revenue of $2.89 billion, well above the $2.68 billion analyst consensus, and adjusted earnings per share (non-GAAP) of $1.39, exceeding the $1.24 expected by analysts. These results marked year-over-year growth of 21% for revenue and 54% for adjusted EPS (non-GAAP). Celestica a ...

DeepSeek曾在半年前，引发全球轰动，无数人撑其为"国运级"的项目。不过，仅半年后，它仿佛"落下神坛"了。试试真的如此吗？我们查看了 QuestMobile发布的《2025年二季度AI应用价值榜》，DeepSeek月均下载量从第一季度的8111.3万降至如今2258.9万，降幅高达72.2%。有人说：这是 DeepSeek爱生成"幻觉"内容导致的，如今，社交媒体上"如何去除DeepSeek的AI味"已成热门话题。当用户反复修改提示词试图消灭文本中的机械感时，一 个残酷问题浮出水面：这位"AI天才少年"，是否正重蹈方仲永的平庸之路？今天，我们将深度探讨这一问题。 去AI味儿运动：当完美文字沦为"机械积木" 在小红书上，搜索"DeepSeek"+"AI味儿"会看到大量的用户在吐槽DeepSeek胡编乱造的内容： 用户@光年之外XXX只是想向AI咨询如何挽回前男友，但DeepSeek给她的措施包括了"向公安备案情感骚扰记录"、"报名南极科考志愿者"以及"攻读清华 大学脑机接口与情感神经学硕士"三种，这让她哭笑不得只能吐槽大模型「完全是在胡说八道」。 用户@螺蛳粉大王XX希望DeepSeek能帮他找到旅游目的地附 ...

智通财经APP获悉，在有报道称AMD(AMD.US)正在考虑将其Instinct MI350系列AI芯片的平均售价从1.5 万美元上调至2.5万美元之后，AMD股价周一收涨4.32%。 值得一提的是，汇丰银行分析师此前就表示看好AMD的MI350系列AI芯片具备与英伟达Blackwell竞争 的能力，并将其对AMD的目标价大幅调升至200美元。汇丰银行还预计，AMD在2026年来自AI芯片的 收入将达到151亿美元，较之前预估的96亿美元大幅提高。 在涨价的消息传出后，富国银行分析师Aaron Rakers领导的团队重申了他们近期对AMD的积极展望，并 上调了对AMD数据中心GPU的销售预期。分析师指出，AMD将于8月5日发布财报，届时投资者的关注 重点将是该公司MI355X数据中心GPU的出货速度和覆盖范围。这一新产品已于6月开始出货。 分析师表示："我们认为，大多数投资者预计MI355X的标价将在约30,000美元左右。"分析师指出， AMD已经表达了其信心，即将在2025财年第三季度恢复GPU营收的同比增长。 分析师目前预计，AMD 2025财年第三季度GPU营收将达到约16.5亿美元，同比略有上升。分 ...

Amkor Technology (NASDAQ:AMKR), a major provider of semiconductor packaging and test services, released its second quarter 2025 results on July 28, 2025. The main headline was a substantial GAAP revenue and earnings beat for Q2 2025. The company delivered $1.51 billion in GAAP revenue. Although profits and revenue both improved from the prior quarter, gross margin (GAAP) contracted from a year ago, reflecting ongoing industry cost pressures. Overall, it was a solid quarter for Amkor as it saw broad-based se ...

Group 1 - Waymo plans to launch a robotaxi service in Dallas next year, expanding its commercial operations which already include Los Angeles and San Francisco [1][6] - The company is partnering with Avis Budget Group to manage its fleet of all-electric autonomous Jaguar I-Pace vehicles, with Avis handling depot operations such as charging and maintenance [1][2] - Waymo has previously partnered with companies like Uber and Moove, but this marks the first collaboration with a rental car company, indicating a potential for future expansions to other cities [2] Group 2 - Waymo has conducted preliminary testing in Dallas, including mapping the city and testing autonomous vehicles on public roads with a human safety operator [3] - The fleet is expected to scale to hundreds of vehicles over time, although specific launch dates and initial fleet size have not been disclosed [4] - Waymo currently operates commercially in five cities and plans to launch services in Washington, D.C., and Miami next year [6]

Starlink providing vital connectivity to the Minas Gerais Fire Department in Brazil 🛰️🚒S.E. Robinson, Jr. (@SERobinsonJr):STARLINK: In Brazil, the Minas Gerais Fire Department has trained over 300 agents, including 174 military firefighters and 132 civilian firefighters to combat vegetation fires during the state's critical fire season.They are utilizing Starlink and the ArcGIS system for https://t.co/l9psbuey6f ...

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed material facts regarding their business operations and prospects [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - Class period is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing collaboration with Novo Nordisk [2][3]. - Defendants are accused of making false statements about the partnership with Novo, which was supposed to ensure access to Wegovy for Hims subscribers, and misrepresenting the offerings of compounded semaglutide products [3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Class period is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [4]. - The complaint alleges that Sarepta misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Specific allegations include failure to disclose significant safety risks associated with ELEVIDYS, misleading statements about trial protocols, and the potential for regulatory scrutiny due to adverse events [4]. - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock price fell by $27.81 per share, or 27.44% [5]. - Subsequent disclosures of additional patient deaths led to further declines in stock price, including a drop of $15.24 per share, or 42.12%, on June 15, 2025 [6].